NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Imunon, Inc. IMNN
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-6.83
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-256.4%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -6.83
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-256.4%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-131.7%
Each USD of equity lost 256 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+0.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.0%
+0.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 12.3M
total assets, end of FY2025
Total assetsUSD 12.3M
EquityUSD 7.1M
CashUSD 8.8M
Current ratio2.32×
Equity funds 57% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−6.83
−16.94
−2.16
−5.03
−3.83
−10.08
−0.77
−0.68
−2.72
−11.89
−1.03
−1.38
−0.95
−3.44
−5.00
−1.52
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−256.4
−211.2
−91.4
−84.3
−55.8
−129.5
−95.2
−50.0
−122.1
−162.7
−84.4
−79.2
−37.9
−139.3
−214.8
·
Shares out B
0.00
0.00
0.01
0.01
0.01
0.00
0.02
0.02
0.02
0.00
0.02
0.02
0.01
0.01
0.03
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed